HPS Pharmacies wish to give notice that Pfizer is experiencing a supply interruption for ergometrine ampoules as follows:
DBL™ Ergometrine Injection
Ergometrine maleate 500mcg/mL
Supplies are expected to return to normal in late December 2018. An internationally registered brand of ergometrine maleate in a 250mcg/mL presentation has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Your HPS Pharmacies Clinical Pharmacist can provide advice on other available alternatives. Please note that any available alternatives are subject to a longer lead time as they must be sourced internationally.
It is imperative that additional care be applied when internationally registered products are used as the presentation may be unfamiliar. Some of the differences that may be encountered include strength and the use of ‘ergonovine’; an interchangeable synonym for ‘ergometrine.’
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Pfizer Australia on 1800 675 229.